Drug-induced corneal complications
2004 · Current Opinion in Ophthalmology · 125 citations
https://doi.org/10.1097/01.icu.0000143688.45232.15
D
David Hollander
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
231
Papers
2.5K
Citations
28
h-index
52
i10-index
David Hollander is an academic researcher from Andover Eye Associates. The author has contributed to research in topics: Ocular Surface and Contact Lens & Glaucoma and retinal disorders & Retinal Diseases and Treatments. The author has an h-index of 28, co-authored 197 publications.
Papers by this author
worksPhase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
2021 · Advances in Therapy · 16 citations
https://doi.org/10.1007/s12325-021-01634-9
Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET)
2023 · Advances in Therapy · 14 citations
https://doi.org/10.1007/s12325-023-02550-w
Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study
2018 · Ocular Immunology and Inflammation · 12 citations
https://doi.org/10.1080/09273948.2018.1432764
Primary graft failure associated with epithelial downgrowth: a case report
2005 · BMC Ophthalmology · 5 citations
https://doi.org/10.1186/1471-2415-5-11
Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study
2020 · Ocular Immunology and Inflammation · 2 citations
https://doi.org/10.1080/09273948.2020.1760309
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat